⚡
CHARGED ALPHA
Stock Detail
Stock Library / GILD
GILD Healthcare

Gilead Sciences

Live stock metrics, chart context, a quarter-by-quarter YouTube archive, and a deeper competitor comparison so this page behaves more like an investor workspace than a flat episode link page.

Company Website Back to Library

Library coverage

Quarters tracked
1
YouTube quarters live
0
Latest video
Pending
YouTube available
No
Current price
$137.64
-1.14 (-0.82%)
Trailing / Forward P/E
20.27x
Forward: 14.31x
Market cap / Volume
—
Volume: —
Revenue / Earnings Growth
4.7%
Earnings: 23.4%
Margins
37.4% op
Gross: 78.8% · Net: 28.9%
Balance sheet
1.55x current
Debt / Equity: 112.9
52-week range / Beta
$93.37 - $157.29
Beta: 0.40
Analyst target
$158.36
Upside: 15.1%
Cash / shareholder return
4.41% FCF yield
Dividend yield: 2.28%

Company context

Industry: Drug Manufacturers - General
Country: United States
Employees: —
Price to book: 7.52x
Return on equity: 40.7%
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Price chart

Market context for GILD

Competitive view

GILD vs. two close competitors

This section compares the current company against two nearby peers on valuation, growth, margins, balance-sheet strength, and investment setup. Green generally marks the strongest relative figure for that row, while red marks the weakest.

Gilead Sciences
GILD
Latest video
YouTube link pending
Growth profile looks strong right now, with above-average top-line and/or earnings momentum.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Balance-sheet leverage is elevated, so investors should watch refinancing costs and how much flexibility management really has.
UnitedHealth Group
UNH
YouTube
Latest video
Q1 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Cash generation stands out versus market value, which helps the stock absorb valuation pressure better than weaker cash converters.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Merck & Co.
MRK
YouTube
Latest video
Q1 2026
Growth is positive but not explosive, which usually supports a steadier compounding case than a hyper-growth story.
Profitability is a real strength here, with healthy operating margins helping support resilience through weaker cycles.
Valuation looks more grounded than many growth names, which can improve the risk/reward if fundamentals hold up.
Risk profile looks relatively manageable compared with many peers, especially if operating execution remains stable.
Market Cap
More scale can mean deeper resources and resilience, although bigger does not automatically mean better upside.
GILD
$170.84B
Gilead Sciences
UNH
$294.66B
UnitedHealth Group
MRK
$294.39B
Merck & Co.
Trailing P/E
Lower trailing P/E can indicate a cheaper valuation relative to trailing earnings, but it may also reflect slower growth or higher perceived risk.
GILD
20.3x
Gilead Sciences
UNH
24.5x
UnitedHealth Group
MRK
16.4x
Merck & Co.
Forward P/E
Forward P/E is often a better read on what investors are paying for the next year of earnings power.
GILD
14.3x
Gilead Sciences
UNH
16.1x
UnitedHealth Group
MRK
12.2x
Merck & Co.
Revenue Growth
Higher revenue growth usually signals stronger demand, market share gains, or a business still in expansion mode.
GILD
4.7%
Gilead Sciences
UNH
12.3%
UnitedHealth Group
MRK
5.0%
Merck & Co.
Earnings Growth
Faster earnings growth matters because it shows management is converting sales momentum into shareholder value.
GILD
23.4%
Gilead Sciences
UNH
-99.9%
UnitedHealth Group
MRK
-19.3%
Merck & Co.
Operating Margin
Higher operating margin suggests better operating discipline, pricing power, or a structurally stronger business model.
GILD
37.4%
Gilead Sciences
UNH
0.3%
UnitedHealth Group
MRK
32.8%
Merck & Co.
Gross Margin
Gross margin helps show how much product-level pricing power and unit economics a company has before overhead.
GILD
78.8%
Gilead Sciences
UNH
18.5%
UnitedHealth Group
MRK
77.2%
Merck & Co.
Net Margin
Higher net margin means more of each dollar of revenue reaches the bottom line after all costs.
GILD
28.9%
Gilead Sciences
UNH
2.7%
UnitedHealth Group
MRK
28.1%
Merck & Co.
Return on Equity
ROE shows how efficiently management turns shareholder capital into profits, though leverage can inflate it.
GILD
40.7%
Gilead Sciences
UNH
12.5%
UnitedHealth Group
MRK
36.9%
Merck & Co.
Free Cash Flow Yield
Higher free cash flow yield can indicate a stronger cash return relative to the stock's market value.
GILD
4.4%
Gilead Sciences
UNH
4.7%
UnitedHealth Group
MRK
4.0%
Merck & Co.
Debt to Equity
Lower leverage usually means less balance-sheet risk, though capital-intensive sectors naturally run higher debt loads.
GILD
112.92x
Gilead Sciences
UNH
81.62x
UnitedHealth Group
MRK
95.96x
Merck & Co.
Current Ratio
A stronger current ratio usually signals better short-term liquidity and more room to absorb shocks.
GILD
1.55x
Gilead Sciences
UNH
0.79x
UnitedHealth Group
MRK
1.54x
Merck & Co.
Beta
Lower beta often means lower volatility versus the market, while higher beta usually brings a rougher ride.
GILD
0.40
Gilead Sciences
UNH
0.41
UnitedHealth Group
MRK
0.28
Merck & Co.
Dividend Yield
Dividend yield matters for income-focused investors, but a high yield can also reflect a stressed stock price.
GILD
2.3%
Gilead Sciences
UNH
2.8%
UnitedHealth Group
MRK
2.8%
Merck & Co.
Analyst Upside
Higher analyst upside suggests the Street still sees room between current price and consensus fair value.
GILD
15.1%
Gilead Sciences
UNH
11.0%
UnitedHealth Group
MRK
9.0%
Merck & Co.

YouTube timeline

Quarterly archive for GILD

Each row is one quarter. Only the YouTube link is shown here for now.

Q1 2026
Video pending
Pending link pending
Quarterly earnings-analysis entry for Gilead Sciences. Use the YouTube link on the right to jump straight into that quarter's video when it is live.
No verified YouTube link yet